Surgalign Holdings ( ) - 株価, ニュースと分析OTCPK:SRGA.Q

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

SRGA.Q 株式概要

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

会社概要

SRGA.Q ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

リスク分析

過去5年間で収益は年間9.6%減少しました。

意味のある時価総額がありません ( $165K )

マイナスの株主資本

過去3か月間の株価の変動は非常に激しい

+2 さらなるリスク

Surgalign Holdings, Inc. 競合他社

Sientra

OTCPK:SIEN.Q

US$388.3k

InVitro International

OTCPK:IVRO

US$1.4m

SmileDirectClub

OTCPK:SDCC.Q

US$1.8m

Procyon

OTCPK:PCYN

US$1.7m

価格と性能

の歴代最高値、変動、値下がりまとめSurgalign Holdings
過去の株価
現在の株価	US$0.018
52週高値	US$4.00
52週安値	US$0.005
ベータ	1.49
11ヶ月の変化	63.64%
3ヶ月変化	-80.00%
1年変化	-99.50%
33年間の変化	-99.97%
5年間の変化	-99.99%
IPOからの変化	-100.00%

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

株主還元

	SRGA.Q	US Medical Equipment	US 市場
7D	16.1%	0.6%	0.5%
1Y	-99.5%	0.03%	23.9%

業界別リターン: SRGA.Q過去 1 年間で1.7 % の収益を上げたUS Medical Equipment業界を下回りました。

リターン対市場: SRGA.Qは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	7.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

安定した株価: SRGA.Qの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: SRGA.Qの週次ボラティリティは、過去 1 年間で28%から40%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. 基礎のまとめ

Surgalign Holdings の収益と売上を時価総額と比較するとどうか。
SRGA.Q 基礎統計学
時価総額	US$165.30k
収益（TTM）	-US$50.49m
売上高(TTM)	US$78.12m

0.0x

P/Sレシオ

0.0x

PER（株価収益率

SRGA.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
SRGA.Q 損益計算書（TTM）
収益	US$78.12m
売上原価	US$26.03m
売上総利益	US$52.09m
その他の費用	US$102.58m
収益	-US$50.49m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-5.50
グロス・マージン	66.68%
純利益率	-64.63%
有利子負債／自己資本比率	-54.1%

SRGA.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

SRGA.Q 株式概要

報酬

リスク分析

Surgalign Holdings, Inc. 競合他社

OTCPK:SIEN.Q

US$388.3k

OTCPK:IVRO

US$1.4m

OTCPK:SDCC.Q

US$1.8m

OTCPK:PCYN

US$1.7m

価格と性能

最新ニュース

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)